A Study to Evaluate ALN-2232 in Participants With Obesity
Recruiting now · Phase 1/Phase 2 · Has a placebo group
Conditions studied: Obesity
In brief
The purpose of this study is to: * evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 co-initiated with tirzepatide in patients with obesity
Key facts
- Study ID
- NCT07463846
- Run by
- Alnylam Pharmaceuticals
- People needed
- 156
- Starts
- 2026-03-02
- Expected to finish
- 2028-03-02
- Last updated by the study team
- 2026-07-23
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- All Parts:
- Has a body mass index (BMI) of ≥30 kg/m\^2 and <40 kg/m\^2
- Has a hemoglobin A1c (HbA1c) <6.5%
You may not qualify if…
- All Parts:
- Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results
- Receiving therapies for chronic weight management or antidiabetic medications
- Note: other protocol defined inclusion/exclusion criteria apply
Where it is running
- Clinical Trial Site — Mount Royal, Canada (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.